Nivolumab and Future Biomarkers in NSCLC

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung metastases.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.